International Journal of Infectious Diseases · 2020 · 15 citations · 8 references
MedicineClinical SciencesInternal MedicineClinical CardiologyInterventional CardiologyPulmonologyAnticoagulant TherapyAnticoagulation TherapyPulmonary EmbolismThromboembolic DiseaseThrombolytic TherapyThrombosisExtended-duration AnticoagulationMassive Pulmonary EmbolismModerate Acute IllnessProphylactic AnticoagulationThrombolysis In Pulmonary Embolism
Severe coronavirus disease 2019 (COVID-19) is known to be associated with a heightened risk of thromboembolism. However, the risk associated with mild and moderate illness from COVID-19 is unknown, and there is no current recommendation for prophylaxis against thromboembolism in patients after hospital treatment, unless there are established thrombophilic risk factors. We report the case of a 52-year-old woman who presented with massive saddle pulmonary embolism 1 week after initial hospital discharge, which was treated successfully with thrombolysis. This case raises the question of whether extended prophylactic anticoagulation should be considered even in low-risk COVID-19 cases.
8
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Dominic Wichmann, Jan‐Peter Sperhake, Marc Lütgehetmann et al. · Annals of Internal Medicine · 2020 · 2.4K citations · Full text
Frederikus A. Klok, Marieke J.H.A. Kruip, Nardo J. M. van der Meer et al. · Thrombosis Research · 2020 · 1.6K citations · Full text